Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker
NCT ID: NCT02322801
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
209 participants
OBSERVATIONAL
2009-03-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pescara, Abruzzo, Italy
Brindisi, Apulia, Italy
Martina Franca, Apulia, Italy
San Cesario di Lecce, Apulia, Italy
San Daniele Del Friuli, Apulia, Italy
Mormanno, Calabria, Italy
Napoli, Campania, Italy
Napoli, Campania, Italy
Scafati, Campania, Italy
Bologna, Emilia-Romagna, Italy
Parma, Emilia-Romagna, Italy
Piacenza, Emilia-Romagna, Italy
Gorizia, Friuli Venezia Giulia, Italy
Trieste, Friuli Venezia Giulia, Italy
Albano Laziale, Lazio, Italy
Rieti, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Viterbo, Lazio, Italy
Arenzano, Liguria, Italy
Savona, Liguria, Italy
Cremona, Lombardy, Italy
Legnano, Lombardy, Italy
Milan, Lombardy, Italy
Milan, Lombardy, Italy
Milan, Lombardy, Italy
Monza, Lombardy, Italy
Rozzano, Lombardy, Italy
Cuneo, Piedmont, Italy
Novara, Piedmont, Italy
Pinerolo, Piedmont, Italy
Turin, Piedmont, Italy
Turin, Piedmont, Italy
Cagliari, Sardinia, Italy
Monserrato, Sardinia, Italy
Catania, Sicily, Italy
Catania, Sicily, Italy
Palermo, Sicily, Italy
Palermo, Sicily, Italy
Arezzo, Tuscany, Italy
Florence, Tuscany, Italy
Massa, Tuscany, Italy
Pisa, Tuscany, Italy
Pontedera, Tuscany, Italy
Prato, Tuscany, Italy
Treviso, Veneto, Italy
Valeggio sul Mincio, Veneto, Italy
Venezia, Veneto, Italy
Verona, Veneto, Italy
Vicenza, Veneto, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML21774
Identifier Type: -
Identifier Source: org_study_id